BTMD Relative Valuation
BTMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BTMD is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for BTMD's competitors is 0.42, providing a benchmark for relative valuation. Biote Corp Corp (BTMD) exhibits a P/S ratio of 0.60, which is 42.24% above the industry average. Given its robust revenue growth of 4.67%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
SMRT
SmartRent Inc
0.843
USD
-2.54%
JAKK
JAKKS Pacific Inc
21.110
USD
-0.89%
PSTL
Postal Realty Trust Inc
13.410
USD
+0.22%
DENN
Denny's Corp
4.010
USD
0.00%
ATYR
aTyr Pharma Inc
3.400
USD
-1.16%
EXFY
Expensify Inc
2.420
USD
0.00%
TNGX
Tango Therapeutics Inc
2.780
USD
+21.40%
TPVG
Triplepoint Venture Growth BDC Corp
6.930
USD
-0.72%
TBN
Tamboran Resources Corp
20.000
USD
0.00%
VALN
Valneva SE
6.340
USD
0.00%
FAQ
Is Biote Corp (BTMD) currently overvalued or undervalued?
Biote Corp (BTMD) is now in the Fair zone, suggesting that its current forward PE ratio of 9.88 is considered Fairly compared with the five-year average of 0.53. The fair price of Biote Corp (BTMD) is between 1.70 to 5.35 according to relative valuation methord.
What is Biote Corp (BTMD) fair value?
How does BTMD's valuation metrics compare to the industry average?
What is the current P/B ratio for Biote Corp (BTMD) as of May 20 2025?
What is the current FCF Yield for Biote Corp (BTMD) as of May 20 2025?
What is the current Forward P/E ratio for Biote Corp (BTMD) as of May 20 2025?